Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Cognition Therapeutics, Inc. - Common Stock (NQ: CGTX ) 0.6480 +0.0340 (+5.54%) Streaming Delayed Price Updated: 1:00 PM EST, Dec 24, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 2,849,569 Open 0.6144 Bid (Size) 0.6360 (10) Ask (Size) 0.6545 (71) Prev. Close 0.6140 Today's Range 0.6002 - 0.6771 52wk Range 0.3400 - 2.950 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Topline Results Are In: Cognition Therapeutics’ Drug To Fight Dementia With Lewy Bodies Shows Encouraging Results In Phase 2 Trial December 20, 2024 Topline Results Are In: Cognition Therapeutics’ Drug To Fight Dementia With Lewy Bodies Shows Encouraging Results In Phase 2 Trial Via News Direct Exposures Product Safety 12 Health Care Stocks Moving In Wednesday's Pre-Market Session December 18, 2024 Via Benzinga Performance YTD -66.60% -66.60% 1 Month +59.21% +59.21% 3 Month +32.73% +32.73% 6 Month -63.18% -63.18% 1 Year -63.18% -63.18% More News Read More Why Is Penny Stock Cognition Therapeutics Trading Over 93% On Wednesday? December 18, 2024 Via Benzinga Cognition Therapeutics Announces Positive Results in Phase 2 Study of CT1812 in Dementia with Lewy Bodies December 18, 2024 From Cognition Therapeutics, Inc. Via GlobeNewswire Cognition Therapeutics Announces all Participants have Completed their Final Visits in the Phase 2 SHIMMER Study of CT1812 in Dementia with Lewy Bodies November 26, 2024 From Cognition Therapeutics, Inc. Via GlobeNewswire Cognition Therapeutics’ Analysis Correlates Biomarker Changes with Cognitive Benefit in Alzheimer’s Population November 25, 2024 From Cognition Therapeutics, Inc. Via GlobeNewswire Life Sciences Investor Forum: Presentations Now Available for Online Viewing November 15, 2024 From Virtual Investor Conferences Via GlobeNewswire Cognition Therapeutics Reports Financial Results for the Third Quarter 2024 and Provides Business and Clinical Update November 13, 2024 From Cognition Therapeutics, Inc. Via GlobeNewswire Life Sciences Investor Forum Agenda Announced for November 14th November 12, 2024 From Virtual Investor Conferences Via GlobeNewswire Cognition Therapeutics to Present at Zacks SCR Life Sciences Investor Forum November 12, 2024 From Cognition Therapeutics, Inc. Via GlobeNewswire November’s Small-Cap Treasures: 3 Stocks Poised for Growth November 04, 2024 Via MarketBeat Topics Economy Exposures Economy Cognition Therapeutics Presents Poster of Participant Demographics from Phase 2 Dementia with Lewy Bodies Study at CTAD October 31, 2024 From Cognition Therapeutics, Inc. Via GlobeNewswire Cognition Therapeutics Announces Results of Pre-specified Analysis of SHINE Study Data Presented at CTAD October 29, 2024 From Cognition Therapeutics, Inc. Via GlobeNewswire Analyses from Cognition’s Positive Phase 2 ‘SHINE’ Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease will be Presented in a Podium Presentation at CTAD October 23, 2024 From Cognition Therapeutics, Inc. Via GlobeNewswire Cognition Therapeutics Releases New Episode of “Conversations” Podcast: Executing Clinical Research in Dementia with Lewy Bodies (DLB) October 22, 2024 From Cognition Therapeutics, Inc. Via GlobeNewswire Cognition Therapeutics Will Participate in the Roth Healthcare Opportunities Conference October 02, 2024 From Cognition Therapeutics, Inc. Via GlobeNewswire Cognition Therapeutics Supports Lewy Body Dementia Awareness Month and the Need for Improved Treatments for the Second Most Common Dementia October 01, 2024 From Cognition Therapeutics, Inc. Via GlobeNewswire 12 Health Care Stocks Moving In Monday's After-Market Session September 30, 2024 Via Benzinga Cognition Therapeutics to Participate in Upcoming September 2024 Investor Conferences September 03, 2024 From Cognition Therapeutics, Inc. Via GlobeNewswire Cognition Therapeutics Publishes EEG Findings from Phase 2 SEQUEL Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease August 22, 2024 From Cognition Therapeutics, Inc. Via GlobeNewswire CGTX Stock Earnings: Cognition Therapeutics Beats EPS for Q2 2024 August 08, 2024 Via InvestorPlace Cognition Therapeutics Reports Financial Results for the Second Quarter 2024 and Provides Business and Clinical Update August 08, 2024 From Cognition Therapeutics, Inc. Via GlobeNewswire Cognition Therapeutics to Report Second Quarter 2024 Financial Results August 05, 2024 From Cognition Therapeutics, Inc. Via GlobeNewswire Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday July 30, 2024 Via InvestorPlace Dow Edges Lower; Ventyx Biosciences Shares Plummet July 29, 2024 Via Benzinga Topics Stocks Exposures US Equities Stock Quote API & Stock News API supplied by www.cloudquote.io Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
